Nivolumab,Ipilimumab
BMS
['nivo', 'nivolumab', 'clear,trial', 'ipilimumab', 'clear,result', 'cyclophosphamide', 'icon', 'medsir']
 shares results of phase 2b icon trial. no clear benefit was shown by nivolumab and ipilimumab in combination with anthracyclines and low-dose cyclophosphamide in pts with er+ her-2- metastatic bc (mpfs: 5.1 vs 3.7 months hr0.94; mos: 20.9 vs 19.9 months hr1.13). #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM